Novo Nordisk has introduced its weight-loss medication Wegovy in China following its approval by local health authorities in June.

This launch heightens the pharmaceutical competition against Eli Lilly, whose weight-loss drug has also been approved but is yet to enter the Chinese market.

China, with a population of 1.4 billion, faces a significant obesity challenge, affecting over 180 million people.

In China, four Wegovy injections are priced at 1,400 yuan (£153; $194), notably less than its US price, where a monthly supply costs $1,349.

However, Chinese patients must cover the full cost, as the treatment is not part of national healthcare insurance.

Wegovy, utilizing the active ingredient semaglutide, helps with weight loss by controlling blood sugar and reducing appetite.

Nonetheless, some users may experience side effects such as nausea and potential weight regain after discontinuing.

Approved in the US in 2021, the drug gained popularity partly through social media and celebrity endorsements.

Meanwhile, regulatory bodies like the UK's Medicines and Healthcare products Regulatory Agency caution against misuse, noting cases of non-obese individuals experiencing illness from the drug.

Wegovy's success has propelled Novo Nordisk's market valuation to over $440 billion, making it Europe's most valuable company.